TempraMed Technologies has signed a non-binding letter of intent with CPO Greece to appoint CPO as the exclusive distributor of its temperature-sensitive medication products, VIVI Cap and VIVI Epi, in Greece. The exclusivity depends on CPO meeting minimum purchase obligations, including a 20% annual increase in combined purchases. CPO Greece, part of the established CPO Group, brings strong local pharmacy market experience and distribution infrastructure, supporting TempraMed's strategy to expand through local partners. If finalized, this agreement will mark TempraMed's entry into the Greek market, adding to its growing presence in Europe and other regions.
Bunzl PLC reported stronger-than-expected financial results with an EPS of $0.60, surpassing the $0.56 consensus. Revenue reached $8.04 billion, driven by a 3.2% underlying growth, especially in North America. The operating margin improved to 7.3%, p...
Palo Alto Networks is set to report strong earnings per share (EPS) of $0.98 and revenue of $3.35 billion for the upcoming quarter, reflecting significant growth from last year. Investor optimism is driven by robust cybersecurity sector trends and a ...
Medtronic reported Q3 earnings per share of $1.45, surpassing estimates of $1.39, and revenue of $9.76 billion, above the $9.55 billion consensus. The strong financial results reflect broad demand for its cardiovascular devices. The company raised it...
Dell Technologies is expected to report record second-quarter earnings with EPS around $4.91 and revenue near $44.89 billion, fueled by high demand for its AI-optimized servers. This would mark a significant increase from last year's $29.78 billion a...
Protagonist Therapeutics saw its stock price target raised to $180 by Barclays following the FDA approval of MIMRYLO, a first-in-class drug for polycythemia vera. The approval was based on strong Phase 3 trial results with 76.9% patient response, tri...
